Trial Profile
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Autologous Epstein Barr virus specific T cell therapy Bluebird bio/University College London (Primary)
- Indications Post-transplant lymphoproliferative disorder
- Focus Adverse reactions; Therapeutic Use
- Acronyms ITREC
- 19 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2019 Status changed from not yet recruiting to recruiting.
- 15 Oct 2018 Planned initiation date changed from 15 May 2018 to 1 Feb 2019.